Kringle Pharma, Inc.
4884.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.21B
Close$
Share Statistics
| Market cap | $5.21 Billion |
|---|---|
| Enterprise Value | $3.53 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-133.92 |
| Beta | 0.44 |
| Outstanding Shares | 8,383,017 |
Return
| Return on Equity | -64.56% |
|---|---|
| Return on Assets | -40.49% |
| Return on Invested Capital | -42.84% |
Valuation & Multiples
| P/E Ratio | -5.82 |
|---|---|
| PEG | 11.81 |
| Price to Sales | 16.13 |
| Price to Book Ratio | 4.33 |
| Enterprise Value to Revenue | 10.33 |
| Enterprise Value to EBIT | -4.37 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kringle Pharma, Inc.
17 employees
CEO: Kiichi Adachi Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to addres...